Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and creating meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules and peptides that have the potential to make important contributions to human health.
Sublimity’s proprietary SmPill® technology is a versatile delivery system for solubilizing active therapeutic agents that are otherwise poorly soluble due to their molecular properties. This process involves hydrophobic and hydrophilic phases to reconstitute the active pharmaceutical ingredients (APIs) as polymer-coated minispheres that control the drug release profile and protect the API from degradation. This technology has broad applications for drugs with poor solubility, poor gastrointestinal permeability, a propensity for degradation in the stomach and by heat, or drugs with suboptimal pharmacokinetics. It also provides an avenue to deliver API directly to the gut with a targeted, local approach.
Sublimity’s lead program ST-0529 has been designed using SmPill® technology and is currently being evaluated in a Phase 2b clinical trial for moderate to severe Ulcerative Colitis CYC-202. ST-0529 is an oral formulation of cyclosporine that delivers therapeutic levels of the drug directly to the inflamed colon, while minimizing the side effects typically associated with systemic immunomodulators.
In addition to the CYC-202 study, Sublimity is moving forward with two new treatment programs for GI disease.
The company employees more than 40 staff at our offices in Dublin and Tullamore, Ireland, Solana Beach, California, and Toronto, Canada.
Sublimity’s proprietary SmPill® technology is a versatile delivery system for solubilizing active therapeutic agents that are otherwise poorly soluble due to their molecular properties.